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Various cardiopathological effects have been observed following chemotherapy treatment in cancer 
patients, due to anti-cancer drug-induced cardiotoxicity (CTX). A retrospective study of cancer 
survivors reported a 50% and 10% incidence of hypertension and heart failure respectively following 
treatment with the tyrosine kinase inhibitor sunitinib, licensed to treat pancreatic neuroendocrine 
tumours. The cellular mechanisms underlying CTX are not known. Here, for the first time, we 
compare the potency of sunitinib in both cardiac cells (primary cardiac fibroblasts (CFs)) and cancer 
cells (a pancreatic adenocarcinoma cell line (PANC-1)). 
Adult rat CFs were isolated by bulk collagenase digestion, maintained in culture and used between 
passages 1 ?2. PANC-1 cells, from previously-frozen stocks, were used between passages 41 ?49. Cells 
were treated with sunitinib (0 ? ? ?രA?DŝŶ&Ɛ ? ? ? ? ? ?രA?DŝŶWE- ? ?ĨŽƌ ? ?രŚŽƵƌƉƌŝŽƌƚŽ
epifluorescent imaging for phenotypic assessment. Cell viability was examined by alamar blue assays 
ĨŽůůŽǁŝŶŐ ? ?രŚŽƵƌƐƵŶŝƚŝŶŝďƚƌĞĂƚŵĞŶƚ ? ? ? ? ? ?രA?D ? ? 
Overall, results indicated increased sensitivity of CFs to sunitinib compared with PANC-1 cells. 
Phenotypic changes indicative of cell death, including appearance of intracellular vacuoles, were 
ĞǀŝĚĞŶƚŝŶ&ƐĨŽůůŽǁŝŶŐ ?രA?DƐƵŶŝƚŝŶŝďƚƌĞĂƚŵĞŶƚǁŚĞƌĂƐƐŝŵŝůĂƌĞĨĨĞĐƚs were not induced until 
 ? ?രA?DƚƌĞĂƚŵĞŶƚŝŶWE-1 cells. Alamar blue assays demonstrated a dramatic increase in CF death 
compared to PANC- ?ĚĞĂƚŚĨŽůůŽǁŝŶŐƚƌĞĂƚŵĞŶƚǁŝƚŚ ? ?രA?DƐƵŶŝƚŝŶŝď ? ? ? ? ?A? ? ? ? ?രǀƐ ? ? ? ?A? ? ? ? ?A?
viability) CF vs PANC-1, n=3). A lower IC50 value for sunitinib was required to exert the same effects 
on CF (IC50 ? ? ?രA?D ?ǀƐWE-1 (IC50 ? ? ? ?രA?D ?ĐĞůůǀŝĂďŝůŝƚǇ ? 
These results suggest sunitinib can cause lethal effects in cardiac cells at lower doses than those 
required to induce pancreatic cancer cell death. Future work will aim to identify cellular mechanisms 
responsible for these toxic effects. Parallel studies in cardiac and cancer cells will be beneficial in 
distinguishing how focused anti-cancer drug delivery could be improved to avoid CTX. 
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